Key facts
- AmplifiDX’s last known valuation is $8.0M (Aug 2021).
- It has raised $2.3M across 1 recorded rounds; the latest was Seed Round ($329K) in Jul 2021.
- Notable investors include National Institutes of Health, Joyance Partners, SeedFolio, Avestria Ventures, Cambrian Growth Partners — 11 tracked in total.
- AmplifiDX has filed 1 Form D with the SEC, most recently Jul 2021 ($329K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for AmplifiDX
Funding rounds
1 roundsAbout AmplifiDX
Developer of molecular point-of-care device designed to provide rapid test results in a cost effective way.The company's technology is engineered for fast turnaround and high sensitivity, otherwise only found in laboratory PCR tests a clear and actionable COVID-19 result, the system is linked to mobile devices and it delivers results in as little as half an hour, enabling users to quickly isolate and stop the spread.
- Sector
- Healthcare
- HQ
- Newark, CA, United States
- Founded
- 2020
- Employees
- 3
- Website
- amplifidx.com/
- Ownership
- Privately Held (backing)
AmplifiDX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AmplifiDX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AmplifiDX in its N-PORT filings yet. We sweep new filings monthly.